Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Int J Cancer ; 133(10): 2383-91, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-23649867

ABSTRACT

Rapid and reliable diagnosis of endometrial cancer (EC) in uterine aspirates is highly desirable. Current sensitivity and failure rate of histological diagnosis limit the success of this method and subsequent hysteroscopy is often necessary. Using quantitative reverse transcriptase-polymerase chain reaction on RNA from uterine aspirates samples, we measured the expression level of 20 previously identified genes involved in EC pathology, created five algorithms based on combinations of five genes and evaluated their ability to diagnose EC. The algorithms were tested in a prospective, double-blind, multicenter study. We enlisted 514 patients who presented with abnormal uterine bleeding. EC was diagnosed in 60 of the 514 patients (12%). Molecular analysis was performed on the remnants of aspirates and results were compared to the final histological diagnoses obtained through biopsies acquired by aspiration or guided by hysteroscopy, or from the specimens resected by hysterectomy. Algorithm 5 was the best performing molecular diagnostic classifier in the case-control and validation study. The molecular test had a sensitivity of 81%, specificity of 96%, positive predictive value (PPV) of 75% and negative predictive value (NPV) of 97%. A combination of the molecular and histological diagnosis had a sensitivity of 91%, specificity of 97%, PPV of 79% and NPV of 99% and the cases that could be diagnosed on uterine aspirate rose from 76 to 93% when combined with the molecular test. Incorporation of the molecular diagnosis increases the reliability of a negative diagnosis, reduces the need for hysteroscopies and helps to identify additional cases.


Subject(s)
Endometrial Neoplasms/diagnosis , Uterine Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biopsy/methods , Case-Control Studies , Double-Blind Method , Endometrial Neoplasms/pathology , Female , Humans , Hysterectomy/methods , Hysteroscopy/methods , Middle Aged , Pathology, Molecular/methods , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity , Uterine Hemorrhage/diagnosis , Uterine Hemorrhage/pathology , Uterine Neoplasms/genetics , Uterine Neoplasms/pathology , Young Adult
2.
Menopause ; 15(6): 1132-8, 2008.
Article in English | MEDLINE | ID: mdl-18791486

ABSTRACT

OBJECTIVE: To compare the efficacy and safety of adding ossein-hydroxyapatite compound (OHC) or calcium carbonate (CC) to raloxifene (RLX) therapy for controlling bone loss in postmenopausal women. DESIGN: : Ninety postmenopausal women were assigned to treatment with RLX plus OHC (group 1, 48 women) or RLX plus CC (group 2, 42 women) for up to 3 years in an open-label, comparative study. Ultrasound measurement of amplitude-dependent speed of sound (ADSoS) was used to evaluate mean changes in bone mineral density. The primary endpoint was mean change of ADSoS from baseline. An intention to treat and per protocol analysis were carried out. Adverse effects were also recorded. RESULTS: Over the study period, the mean ADSoS diminished in both groups even though the rate of reduction was higher in the RLX plus CC group, with a mean change in ADSoS score of -18.72 m/s from baseline to year 3 in the RLX plus OHC group and -63.64 m/s in the RLX+CC group (P = 0.006). Similar results were seen on T and Z scores. Adverse effects were infrequent and the number and type were similar between groups. CONCLUSIONS: RLX plus OHC appears to be more effective in controlling bone loss than RLX plus CC for the control of bone loss in postmenopausal women.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Calcium Carbonate/therapeutic use , Durapatite/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Raloxifene Hydrochloride/therapeutic use , Drug Therapy, Combination , Female , Humans , Middle Aged , Patient Satisfaction
3.
Acta Obstet Gynecol Scand ; 86(4): 498-9, 2007.
Article in English | MEDLINE | ID: mdl-17486476

ABSTRACT

The designation'hepatoid carcinoma' has been introduced as a unique type of carcinoma that arises outside the liver but resembles, to a considerable extent, hepatocellular carcinoma both histologically and immunohistochemically in its staining for alpha-fetoprotein (AFP). The minimum histological criteria of hepatoid carcinomas are the evidence of AFP production and abundant eosinophilic cytoplasm. These tumors have been reported in the ovary, the lung, the stomach, the renal pelvis, and the bladder. We, in this study, present a rare patient with primary hepatoid carcinoma of the ovary (OHC) and review the previous reports.


Subject(s)
Carcinoma, Hepatocellular/pathology , Hysterectomy , Liver Neoplasms/pathology , Ovarian Neoplasms/pathology , alpha-Fetoproteins/biosynthesis , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/secondary , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/secondary , Carcinoma, Hepatocellular/surgery , Diagnosis, Differential , Fatal Outcome , Female , Humans , Immunohistochemistry , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Lung Neoplasms/secondary , Neoplasms, Multiple Primary , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/surgery , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...